Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8+T cell function and its impact against pancreatic ductal adenocarcinoma

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-02-27 DOI:10.1080/2162402x.2024.2322173

Wei Wei, Linqing Tian, Xiaoyan Zheng, Lei Zhong, Yuan Chen, Hui Dong, Guibing Zhang, Shibing Wang, Xiangmin Tong

引用次数: 0

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is currently difficult to treat, even when therapies are combined with immune checkpoint blockade (ICB). A novel strategy for immunotherapy would be to maxim...

查看原文本刊更多论文

溶瘤疫苗病毒表达 GPX4 可显著增强 CD8+T 细胞功能及其对胰腺导管腺癌的影响

胰腺导管腺癌（PDAC）目前很难治疗，即使是结合免疫检查点阻断（ICB）疗法也是如此。免疫疗法的一种新策略是最大限度地...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.